Clinical trial of long acting methylphenidate in amphetamine addicts with Attention Deficit Hyperactivity Disorder (ADHD)
Completed
- Conditions
- Attention deficit hyperactivity disorderMental and Behavioural Disorders
- Registration Number
- ISRCTN81602628
- Lead Sponsor
- Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
1. Male or female 18 to 65 years
2. Written consent
3. Amphetemine (amph) dependence according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
4. Used apmh on minimum 10 days during the year before inclusion
5. ADHD according to DSM-IV
6. Living in Stockholm area
Exclusion Criteria
1. Dependence (current or past) of opioids, cannabis or benzodiazepines
2. Have used opioids within 3 months before screening
3. Other serious psychiatric conditions such as suicidality or psychosis
4. Current treatment with benzodiazepines, antidepressants or neuroleptics
5. Heart condition or stroke or any other medical condition that is considered a risk
6. Pregnancy or breastfeeding
8. IQ <75
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in self rated ADHD symptoms, assessed using the Conners' Adult ADHD Rating Scale (CAARS) at baseline and once a week for 12 weeks
- Secondary Outcome Measures
Name Time Method 1. Reduction in drug use: urine toxicology at baseline and weeks 4, 8 and 12 <br>2. Observer rated ADHD symptoms, assessed using CAARS at baseline and once a week for 12 weeks <br>3. Psychiatric symptoms at baseline and weeks 4, 8 and 12 <br>3.1. Self rated craving assessed with Tiffany craving scale <br>3.2. Change in symptoms of depression and anxiety assessed with Becks inventories <br>3.3. Stroop test (test of selective attention)